Journal
GENES
Volume 13, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/genes13050757
Keywords
amyotrophic lateral sclerosis; ALS; single-nucleotide polymorphisms; genotyping; inflammation; oxidative stress; clinical modifiers
Categories
Funding
- Slovenian Research Agency (ARRS) [P3-0054, P1-0170, P3-0338]
Ask authors/readers for more resources
Inflammation and oxidative stress are important factors in ALS disease. This study investigated the impact of genetic variants related to inflammation and oxidative stress on ALS susceptibility and modification. The results showed that certain variants were associated with different clinical characteristics and survival outcomes in ALS patients.
Inflammation and oxidative stress are recognized as important contributors to amyotrophic lateral sclerosis (ALS) disease pathogenesis. Our aim was to evaluate the impact of selected single-nucleotide polymorphisms in genes involved in inflammation and oxidative stress on ALS susceptibility and modification. One-hundred-and-eighty-five ALS patients and 324 healthy controls were genotyped for nine polymorphisms in seven antioxidant and inflammatory genes using competitive allele-specific PCR. Logistic regression; nonparametric tests and survival analysis were used in the statistical analysis. Investigated polymorphisms were not associated with ALS susceptibility. Carriers of at least one polymorphic SOD2 rs4880 T or IL1B rs1071676 C allele more often had bulbar ALS onset (p = 0.036 and p = 0.039; respectively). IL1B rs1071676 was also associated with a higher rate of disease progression (p = 0.015). After adjustment for clinical parameters; carriers of two polymorphic IL1B rs1071676 C alleles had shorter survival (HR = 5.02; 95% CI = 1.92-13.16; p = 0.001); while carriers of at least one polymorphic CAT rs1001179 T allele had longer survival (HR = 0.68; 95% CI = 0.47-0.99; p = 0.046). Our data suggest that common genetic variants in the antioxidant and inflammatory pathways may modify ALS disease. Such genetic information could support the identification of patients that may be responsive to the immune or antioxidant system-based therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available